ArticleBMC cancer2017
A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Article
- Article
- Development and validation of prognostic and diagnostic models utilizing immune checkpoint-related genes in public datasets for clear cell renal cell carcinoma.Frontiers in genetics · 2025Article
- Exploring the Prognostic Value of Tumour-Associated Genes in Clear Cell Renal Cell Carcinoma Through Single-Cell RNA Sequencing Insights.Journal of cellular and molecular medicine · 2024Article
- Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.International urology and nephrology · 2024Article
- High-throughput analysis of tissue microarrays using automated desorption electrospray ionization mass spectrometry.Scientific reports · 2022Article
- Construction and validation of a prognostic model for kidney renal clear cell carcinoma based on podocyte-associated genes.Cancer medicine · 2022Article
- Tumor-Suppressive and Oncogenic Roles of microRNA-149-5p in Human Cancers.International journal of molecular sciences · 2022Review
- Development and verification of a microsatellite instability-related risk signature for predicting survival and therapy effectiveness in gastric cancer.Journal of gastrointestinal oncology · 2022Article
- Vitamin D pathway gene variation rs3740165 is associated with serological uric acid levels in healthy Chinese women.Frontiers in endocrinology · 2022Article
- Article
- Human microsporidian pathogenJournal of cell science · 2021Article
- ENAM gene associated with T classification and inhibits proliferation in renal clear cell carcinoma.Aging · 2021Article
- MiR-149-5p: An Important miRNA Regulated by Competing Endogenous RNAs in Diverse Human Cancers.Frontiers in oncology · 2021Review
- Bioinformatics for The Prognostic Value and Function of Cubilin (CUBN) in Colorectal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Autophagy-related geneAging · 2020Article
- Article
- Article
- Tumoral Pyruvate Kinase L/R as a Predictive Marker for the Treatment of Renal Cancer Patients with Sunitinib and Sorafenib.Journal of Cancer · 2019Article
- Genomic approaches in the search for molecular biomarkers in chronic kidney disease.Journal of translational medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is an unmet clinical need for better prognostic and diagnostic tools for renal cell carcinoma (RCC).
methodsHuman Protein Atlas data resources, including the transcriptomes and proteomes of normal and malignant human tissues, were searched for RCC-specific proteins and cubilin (CUBN) identified as a candidate. Patient tissue representing various cancer types was constructed into a tissue microarray (n = 940) and immunohistochemistry used to investigate the specificity of CUBN expression in RCC as compared to other cancers. Two independent RCC cohorts (n = 181; n = 114) were analyzed to further establish the sensitivity of CUBN as RCC-specific marker and to explore if the fraction of RCCs lacking CUBN expression could predict differences in patient survival.
resultsCUBN was identified as highly RCC-specific protein with 58% of all primary RCCs staining positive for CUBN using immunohistochemistry. In venous tumor thrombi and metastatic lesions, the frequency of CUBN expression was increasingly lost. Clear cell RCC (ccRCC) patients with CUBN positive tumors had a significantly better prognosis compared to patients with CUBN negative tumors, independent of T-stage, Fuhrman grade and nodal status (HR 0.382, CI 0.203-0.719, P = 0.003).
conclusionsCUBN expression is highly specific to RCC and loss of the protein is significantly and independently associated with poor prognosis. CUBN expression in ccRCC provides a promising positive prognostic indicator for patients with ccRCC. The high specificity of CUBN expression in RCC also suggests a role as a new diagnostic marker in clinical cancer differential diagnostics to confirm or rule out RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.